Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
01
03
2023
accepted:
14
06
2023
medline:
17
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Pathogenic variants in the valosin-containing protein ( A 6-item clinical score was developed to evaluate the phenotypic level of evidence to support the pathogenicity of the novel variants. Each item is allocated a value, a score ranging from 0.5 to 5.5 points. A receiver-operating characteristic curve was used to identify a cutoff value of 3 to consider a variant as high likelihood disease associated. The scoring system results were confronted with results of in vitro ATPase activity assays and with in silico analysis. All variants were missense, except for one small deletion-insertion, 18 led to amino acid changes within the N and D1 domains, and 13 increased the enzymatic activity. The clinical score coincided with the functional studies in 17 of 19 variants and with the in silico analysis in 12 of 19. For 12 variants, the 3 predictive tools agreed, and for 7 variants, the predictive tools disagreed. The pooled data supported the pathogenicity of 13 of 19 novel VCP variants identified in the study. This study provides data to support pathogenicity of 14 of 19 novel
Sections du résumé
Background and Objectives
UNASSIGNED
Pathogenic variants in the valosin-containing protein (
Methods
UNASSIGNED
A 6-item clinical score was developed to evaluate the phenotypic level of evidence to support the pathogenicity of the novel variants. Each item is allocated a value, a score ranging from 0.5 to 5.5 points. A receiver-operating characteristic curve was used to identify a cutoff value of 3 to consider a variant as high likelihood disease associated. The scoring system results were confronted with results of in vitro ATPase activity assays and with in silico analysis.
Results
UNASSIGNED
All variants were missense, except for one small deletion-insertion, 18 led to amino acid changes within the N and D1 domains, and 13 increased the enzymatic activity. The clinical score coincided with the functional studies in 17 of 19 variants and with the in silico analysis in 12 of 19. For 12 variants, the 3 predictive tools agreed, and for 7 variants, the predictive tools disagreed. The pooled data supported the pathogenicity of 13 of 19 novel VCP variants identified in the study.
Discussion
UNASSIGNED
This study provides data to support pathogenicity of 14 of 19 novel
Identifiants
pubmed: 37588275
doi: 10.1212/NXG.0000000000200093
pii: NXG-2023-000033
pmc: PMC10427110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e200093Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Déclaration de conflit d'intérêts
The authors report no relevant disclosures. Go to Neurology.org/NG for full disclosure.
Références
J Neurol. 2011 Aug;258(8):1494-6
pubmed: 21387114
J Neurol Sci. 2016 Sep 15;368:352-8
pubmed: 27538664
Muscle Nerve. 2021 Apr;63(4):442-454
pubmed: 33145792
Molecules. 2022 May 17;27(10):
pubmed: 35630670
Neuron. 2010 Dec 9;68(5):857-64
pubmed: 21145000
Neuromuscul Disord. 2021 Aug;31(8):701-705
pubmed: 34244020
Brain. 2014 Nov;137(Pt 11):2897-902
pubmed: 25125609
Mol Genet Metab. 2001 Dec;74(4):458-75
pubmed: 11749051
Acta Myol. 2015 Dec;34(2-3):95-108
pubmed: 27199536
Orphanet J Rare Dis. 2020 Sep 29;15(1):267
pubmed: 32993728
Clin Genet. 2013 May;83(5):422-31
pubmed: 22909335
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Neuromuscul Disord. 2011 Aug;21(8):551-5
pubmed: 21684747
J Clin Neurosci. 2019 Jun;64:8-10
pubmed: 30955949
Neuromuscul Disord. 2020 Mar;30(3):232-235
pubmed: 32165109
Science. 2020 Nov 20;370(6519):
pubmed: 33004675
Int J Mol Sci. 2020 May 28;21(11):
pubmed: 32481679
Neuromuscul Disord. 2009 May;19(5):308-15
pubmed: 19380227
J Cell Sci. 2014 Sep 15;127(Pt 18):3877-83
pubmed: 25146396
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Ann Neurol. 2005 Mar;57(3):457-61
pubmed: 15732117
Hum Mol Genet. 2006 Jan 15;15(2):189-99
pubmed: 16321991
Front Cell Dev Biol. 2019 Dec 04;7:313
pubmed: 31867326
Neuromuscul Disord. 2016 Aug;26(8):535-47
pubmed: 27312024
Case Rep Genet. 2015;2015:239167
pubmed: 25878907
Neuromuscul Disord. 2018 Jun;28(6):491-501
pubmed: 29754758
JAMA Neurol. 2016 Sep 1;73(9):1105-14
pubmed: 27400454
J Mol Biol. 2014 Jul 29;426(15):2886-99
pubmed: 24878061
Neurology. 2012 Nov 27;79(22):2201-8
pubmed: 23152587
J Neurol Neurosurg Psychiatry. 2022 Jul 27;:
pubmed: 35896379
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
J Med Genet. 2012 Jan;49(1):41-6
pubmed: 21984748
Clin Transl Sci. 2014 Feb;7(1):29-32
pubmed: 24119107
Front Neurosci. 2019 Dec 06;13:1289
pubmed: 31866807
Brain. 2012 Dec;135(Pt 12):e223; author reply e224
pubmed: 22991237
Eur J Neurol. 2013 Feb;20(2):251-8
pubmed: 22900631
J Biol Chem. 2012 Mar 9;287(11):8561-70
pubmed: 22270372
Genes (Basel). 2023 Mar 08;14(3):
pubmed: 36980948
Neuromuscul Disord. 2015 Apr;25(4):289-96
pubmed: 25617006